A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023.
The company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Novo Nordisk , which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported soaring sales.
For 2023, the company now anticipates sales growth of 27%-33% and operating profit growth of 31%-37%, at constant exchange rates.
The active ingredient in Wegovy is semaglutide, an FDA-approved drug that works by imitating a naturally-occurring gut hormone that helps to regulate appetite.
Persons:
Wegovy, Lars Fruergaard Jørgensen, — Sam Meredith
Organizations:
Novo Nordisk, FDA
Locations:
Chicago , Illinois, U.S, Danish